This is a working overview of adipose tissue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-08 and is reviewed periodically as new material appears.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
==== Muscle fibers ==== Typically muscle fibers surround the hydrostatic body. There are two main types of muscle fibers orientations that are responsible for the movement: the circular orientations and longitudinal orientations. Circular muscles decrease the diameter of a hydrostatic body, resulting in an increase in the length of the body, whereas longitudinal muscles shortens the length of a hydrostatic body, resulting in an increase in the diameter of the body. There are four categories of movements of a hydrostatic skeleton: elongation, shortening, bending and torsion. Elongation, which involves an increase in the length of a hydrostatic body requires either circular muscles, a transverse muscle arrangement, or radial muscle arrangement. For a transverse muscle arrangement, parallel sheets of muscle fibers that extend along the length of a hydrostatic body. For a radial muscle arrangement, radial muscles radiate from a central axis along the axis perpendicular to the long axis. Shortening involves the contraction of the longitudinal muscle. Both shortening and bending involve the contraction of longitudinal muscle, but for bending motion some of the antagonistic muscles work synergistically with longitudinal muscles. The amplitude of movements are based upon the antagonistic muscles forces and the amount of leverage the antagonistic muscle provides for movement. For the torsion motion, muscles are arranged in helical layers around a hydrostatic body.
The evidence for brain-derived neurotrophic factor (BDNF) in mediating some of the neurobiological effects of physical exercise was noted in one review which hypothesized that increased BDNF signaling is responsible for the antidepressant effect. A meta-analysis of 15 studies published in 2022 suggested a curvilinear dose-response relationship between exercise and depression risk, with low levels of exercise showing the best dose-response.
== Entrances extant today == Ninety-one Guimard entrances survived until 1970. Eighty-six are still extant and protected as historical monuments; six were protected in 1965, the remainder in 1978. These include two original Type B édicules: at Porte Dauphine, on its original site and with the wall panels, and at Abbesses (moved from Hôtel de Ville in 1974). A third Type B of varying form at Châtelet is a 2000 recreation. The remainder of the preserved entrances are simple enclosures or entourages, with or without the light and sign arch. In addition, two sides of an entourage form an entryway to the headquarters building of the RATP.
All octopuses and most cephalopods are considered to be color blind. Coleoid cephalopods (octopus, squid, cuttlefish) have a single photoreceptor type and lack the ability to determine color by comparing detected photon intensity across multiple spectral channels. When camouflaging themselves, they use their chromatophores to change brightness and pattern according to the background they see, but their ability to match the specific color of a background may come from cells such as iridophores and leucophores that reflect light from the environment. They also produce visual pigments throughout their body and may sense light levels directly from their body. Evidence of color vision has been found in the sparkling enope squid (Watasenia scintillans). It achieves color vision with three photoreceptors, which are based on the same opsin, but use distinct retinal molecules as chromophores: A1 (retinal), A3 (3-dehydroretinal), and A4 (4-hydroxyretinal). The A1-photoreceptor is most sensitive to green-blue (484 nm), the A2-photoreceptor to blue-green (500 nm), and the A4-photoreceptor to blue (470 nm) light. In 2015, a novel mechanism for spectral discrimination in cephalopods was described. This relies on the exploitation of chromatic aberration (wavelength-dependence of focal length). Numerical modeling shows that chromatic aberration can yield useful chromatic information through the dependence of image acuity on accommodation.
Sources: en.wikipedia.org
Gliomas (glial cell tumors) Oligoastrocytoma, Choroid plexus papilloma, Ependymoma, Astrocytoma (Pilocytic astrocytoma, Glioblastoma multiforme), Dysembryoplastic neuroepithelial tumour, Oligodendroglioma, Medulloblastoma, Primitive neuroectodermal tumor Neuroepitheliomatous tumors Ganglioneuroma, Neuroblastoma, Atypical teratoid rhabdoid tumor, Retinoblastoma, Esthesioneuroblastoma Nerve sheath tumors Neurofibroma (Neurofibrosarcoma, Neurofibromatosis), Schwannoma, Neurinoma, Acoustic neuroma, Neuroma
zone melting Any of several methods of purifying crystalline solids which involve applying heat to a small region of a larger solid (particularly a metal ingot) until localized melting occurs, creating a molten zone which is then slowly moved along the surface to other parts of the solid by moving the target of the heating element. As it moves, the forward edge of the molten zone continuously melts new areas of impure solid, while leaving a path of purer solid behind it as previously melted areas are cooled and resolidified; because the molten liquid phase can hold a higher concentration of impurities than the solid phase, the impurities of melted areas tend to concentrate in the molten zone and be carried along as it moves, leaving behind regions with fewer impurities. The process is commonly used in the refinement of high-purity metalloids for use in semiconductors.
Despite many advantages that the concept of hypercycles presents, there were also some problems regarding the traditional model formulation using ODEs: a vulnerability to parasites and a limited size of stable hypercycles. In 2012, the first experimental proof for the emergence of a cooperative network among fragments of self-assembling ribozymes was published, demonstrating their advantages over self-replicating cycles. However, even though this experiment proves the existence of cooperation among the recombinase ribozyme subnetworks, this cooperative network does not form a hypercycle per se, so we still lack the experimental demonstration of hypercycles.
Sources: en.wikipedia.org
A study at Duke–NUS Medical School found that healthy muscle releases molecular signals into the bloodstream protecting against tumor growth throughout the body, that the amount of such signals declines with age, and that exercise can restore and protect the ability of aging muscles to send these signals.
Moisture buildup in buildings may arise from water penetrating areas of the building envelope or fabric, from plumbing leaks, rainwater or groundwater penetration, or from condensation due to improper ventilation, insufficient heating or poor thermal quality of the building envelope. Even something as simple as drying clothes indoors on radiators can increase the risk of mold growth, if the humidity produced is not able to escape the building via ventilation. Mold predominantly affects the airways and lungs. Known effects of mold on health include asthma development and exacerbation, with children and elderly at greater risk of more severe health impacts. Infants in homes with mold have a much greater risk of developing asthma and allergic rhinitis. More than half of adult workers in moldy or humid buildings suffer from nasal or sinus symptoms due to mold exposure. Some varieties of mold contain toxic compounds (mycotoxins). However, exposure to hazardous levels of mycotoxin via inhalation is not possible in most cases, as toxins are produced by the fungal body and are not at significant levels in the released spores.
=== Baking powder === Malaysian authorities determined that ammonium bicarbonate, not milk, imported from China was the source of contamination at the Khong Guan and Khian Guan biscuit factory. Malaysian authorities said it was probable cross contamination of batches from Chinese companies Broadtech Chemical Int. Co Ltd, Dalian Chemical Industries and Tianjin Red Triangle International Trading Co, and did not suspect adulteration. On 19 October, Taiwanese authorities detected melamine in 469 tons of ammonium bicarbonate imported from China. Samples tested showed up to 2,470ppm of melamine.
SMRT sequencing is based on the sequencing by synthesis approach. The DNA is synthesized in zero-mode wave-guides (ZMWs) – small well-like containers with the capturing tools located at the bottom of the well. The sequencing is performed with use of unmodified polymerase (attached to the ZMW bottom) and fluorescently labelled nucleotides flowing freely in the solution. The wells are constructed in a way that only the fluorescence occurring by the bottom of the well is detected. The fluorescent label is detached from the nucleotide upon its incorporation into the DNA strand, leaving an unmodified DNA strand. According to Pacific Biosciences (PacBio), the SMRT technology developer, this methodology allows detection of nucleotide modifications (such as cytosine methylation). This happens through the observation of polymerase kinetics. This approach allows reads of 20,000 nucleotides or more, with average read lengths of 5 kilobases. In 2015, Pacific Biosciences announced the launch of a new sequencing instrument called the Sequel System, with 1 million ZMWs compared to 150,000 ZMWs in the PacBio RS II instrument. SMRT sequencing is referred to as "third-generation" or "long-read" sequencing.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.